COVID-19 Vaccines and Treatment: The Race for Global Equity
We have stopped tracking COVID-19 bivalent vaccine purchases, vaccine donations, and therapeutics data as of May 5, 2023. The latest data update available on the website includes bivalent vaccine purchases, vaccine donations, and therapeutics data. Data on the COVID-19 vaccine purchases and manufacturing data was last updated July 1, 2022 and is also available on the website. The latest date can be downloaded here: https://launchandscalefaster.org/COVID-19.
As always, please let us know if you have any questions or spot any gaps or discrepancies in the data, and if you have found the data useful we would love to hear how you have used it.
For further questions or other media requests, please email Melissa Estrada, firstname.lastname@example.org.
Our team aggregates and analyzes publicly available data to track the purchases, manufacturing, and donations of COVID-19 vaccines and therapeutics. The data are provided in interactive visuals on this site, as well as in a downloadable spreadsheet (updated regularly), to strengthen data-driven understandings of the global equity challenges and potential solutions in pandemic response. Please contact us at email@example.com with any additions or corrections to the data presented here.
Latest COVID-19 Vaccine and Therapeutics Data
We are at an exceedingly perilous and urgent moment in the COVID-19 pandemic. As the Delta variant has demonstrated, we are fighting a virus that doesn’t respect borders and rapidly advances across continents. If the virus continues to circulate unchecked in large parts of the world, we will see not only many more millions of infections and deaths, but also new variants that could totally pierce vaccine immunity, returning the world to square one.
We are at an exceedingly perilous and urgent moment in the COVID-19 pandemic. The Delta variant, vastly more dangerous and pernicious than the original SARS-CoV-2 virus, has rapidly spread worldwide. It has been driving a deadly summer surge in the US; ripping through Latin America; causing Indonesia to become the next Asian hotspot; and fueling a third wave of the pandemic in Africa, where less than two percent of the population has been fully vaccinated. To respond, the US must build on the rapid development and availability of its highly effective vaccines – ensuring easy access for any American who wants to be vaccinated, and readiness to rapidly deploy boosters and vaccines for children. But as Delta has shown, an effective domestic response is not enough. Read more here.
Read The Hill's July 8, 2021article: Beyond ample supply, hurdles abound in the race to vaccinate the globe
Our research has recently been featured in The New York Times, The Washington Post, The Economist, Bloomberg, and The Guardian and many other outlets, including El Diario in Spain, as well as Al Jazeera. View and listen to these brief commentaries from our research team on BBC, NPR, NYPoficial (Paraguay) and ABC News.
Featuring Dr. Krishna Udayakumar, Director, Duke GHIC - VOX, April 28, 2021
Dr. Ernesto Ortiz, Senior Manager - CNN Espanol, February 22, 2021
For Media Requests please email Jessica Harris at firstname.lastname@example.org or call + 1 919 668 7923.
These data and analyses are updated every week. We are tracking the data to the best of our ability, though there may be gaps given the speed of developments and lack of detailed information in many public statements.
Suggested citation: Duke Global Health Innovation Center. (2021). Launch and Scale Speedometer. Duke University. Retrieved from: https://launchandscalefaster.org/covid-19
Except where otherwise noted, this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.